Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Companhia é pioneira no país a utilizar água da chuva captada e purificada dentro da própria empresa para produzir insulina ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.